SCHEMBL6715174

SCHEMBL6715174

O=C(c1ccc(Cl)s1)N1CCN(c2ccc(NCc3cn(C(c4ccccc4)(c4ccccc4)c4ccccc4)cn3)cc2)CC1

nearest known ligand 0.54

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
MAPT P10636 7/20 0.54
LMNA P02545 4/20 0.42
ALDH1A1 P00352 4/20 0.42
HTT P42858 3/20 0.42
SMN1; SMN2 Q16637 2/20 0.42
GAA P10253 2/20 0.41
ALOX15 P16050 2/20 0.41
ALOX12 P18054 2/20 0.41
MAPK1 P28482 2/20 0.41
GFER P55789 1/20 0.41
KMT2A Q03164 2/20 0.39
TP53 P04637 1/20 0.39
HPGD P15428 1/20 0.38
L3MBTL1 Q9Y468 3/20 0.38
MEN1 O00255 1/20 0.38
SLC6A7 Q99884 1/20 0.38
NPY2R P49146 1/20 0.38
HTR1A P08908 1/20 0.38
KDM4E B2RXH2 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6711285 0.86 MAPT (0.53) MAPTLMNAALDH1A1HTTSMN1; SMN2
SCHEMBL6711131 0.85 MAPT (0.41) MAPTLMNAALDH1A1HTTSMN1; SMN2
SCHEMBL6714778 0.76 KDM1A (0.41) MAPTALDH1A1GAAALOX15ALOX12
SCHEMBL6711176 0.75 LMNA (0.42) MAPTLMNAALDH1A1HTTSMN1; SMN2
SCHEMBL6709635 0.74 MAPT (0.48) MAPTLMNAALDH1A1HTTSMN1; SMN2
SCHEMBL6715237 0.73 MAPT (0.56) MAPTLMNAALDH1A1HTTSMN1; SMN2
SCHEMBL6710873 0.72 SMN1; SMN2 (0.62) MAPTLMNAALDH1A1HTTSMN1; SMN2
SCHEMBL6709607 0.72 MAPT (0.54) MAPTLMNAALDH1A1HTTSMN1; SMN2
SCHEMBL6709643 0.69 MAPT (0.48) MAPTLMNAALDH1A1HTTSMN1; SMN2
SCHEMBL8644544 0.67 CYP3A4 (0.43) GAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040092524-A1 Novel aminophenyl piperazine or aminophenyl piperidine derivatives inhibiting prenyl transferase proteins and method for preparing same PIERRE FABRE MEDICAMENT (FR) 2004-05-13 US disclosed
EP-1324999-A1 NOVEL AMINOPHENYL PIPERAZINE OR AMINOPHENYL PIPERIDINE DERIVATIVES INHIBITING PRENYL TRANSFERASE PROTEINS AND METHODS FOR PREPARING SAME PIERRE FABRE MEDICAMENT (FR) 2003-07-09 EP disclosed
WO-2002030927-A1 NOVEL AMINOPHENYL PIPERAZINE OR AMINOPHENYL PIPERIDINE DERIVATIVES INHIBITING PRENYL TRANSFERASE PROTEINS AND METHODS FOR PREPARING SAME PIERRE FABRE MEDICAMENT (FR) 2002-04-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040092524-A1 Novel aminophenyl piperazine or aminophenyl piperidine derivatives inhibiting prenyl transferase proteins and method for preparing same CBR3, CBR1, HCCS MAPT 4753/4885LMNA 2447/4885ALDH1A1 3031/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.